Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CONX vs ABVC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–1 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: CONX 1 – 3 ABVC (2 Tie) Matrix Metrics: CONX 1 – 7 ABVC

As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY).
  • Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CONX vs ABVC
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.88β · 135% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $4.23 · SMA50: $5.78
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap $24.5M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.34β · 56% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 32.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.7 · SMA20: $1.00 · SMA50: $1.02

6-Pillar Scorecard Institutional Category Breakdown (CONX 1 – 3 ABVC)

Columns: Metric · CONX · ABVC
1. Valuation Multiples ABVC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 30.8x
2. Growth & Scale ABVC
Revenue Growth (YoY) N/A +104.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $797,916
Market Cap N/A $24.5M
3. Profitability & Quality ABVC
Gross Margin N/A 100.0%
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -52.7%
4. Balance Sheet & Cash Flow CONX
Cash Generation (TTM) N/A -$5.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.49 Book/Sh · -52.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CONX (1) vs ABVC (7)
Institutional Metric CONX ABVC Criterion Row Edge
Market Capitalization
Scale
N/A $24.5M Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +104.5% Higher Growth ABVC
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ABVC
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
N/A -52.7% Higher ROE ABVC
52-Week Range Position
Momentum
0% ($3–$28) 10% ($1–$3) Stronger Trend ABVC
Beta / 30D Volatility
Risk Regime
4.88β · 135% Vol 1.34β · 56% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 39.0 / 100 (SELL) Higher Composite CONX
Trailing 12M Revenue (USD)
Operating Scale
N/A $797,916 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 30.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$5.8M EBITDA ($0.49 Book/Sh · -52.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +57.07 pp
CONX: -54.66% · ABVC: +2.41%
3M Horizon ABVC +52.87 pp
CONX: -44.34% · ABVC: +8.53%
6M Horizon ABVC +59.11 pp
CONX: -71.26% · ABVC: -12.15%
1Y Horizon ABVC +23.53 pp
CONX: -88.97% · ABVC: -65.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs ABVC. Trailing 12-month operating profitability (CONX N/A vs ABVC 0.0%) and valuation multiples (CONX N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $24.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CONX vs ABVC Key Questions & Quantitative Answers

As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY). Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: CONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, CONX generates N/A in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, CONX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.

ABVC screens cheaper on headline valuation multiples. CONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CONX (N/A ROE) versus ABVC (-52.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CONX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 135% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.